Professor, Department of Internal Medicine, Seoul National University College of Medicine
Hyo-Soo Kim, MD/PhD/FAHA/FACC
- Professor, Department of Internal Medicine, Seoul National University College of Medicine
- Director, Director of Strategic Center of CBT (Cell & Bio Therapy) for Hear, Diabetes, & Caner, Seoul National University Hospital
- Current President, Korean Society of Cardiology (KSC) 2020-2022
- Past President, Korean Society of Interventional Cardiology (KSIC) (2016~2018)
- Past President, Korean Society of Lipid & Atherosclerosis (KSoLA) (2016~2018)
- Chairman, Board of Directors, Foundation for Medical Innovation (FMI) (2015~2018)
- President Elect, APSC (Asian Pacific Society of Cardiology) (2021-2023)
- MAJOR PAPERS:
Position | Title | Journal | Year | Impact factor |
Corresponding author | Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial | Lancet. 2021 Jun 26;397(10293):2487-2496. | 2021 | 79.321 |
First author | Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial | Lancet. 2020 Oct 10;396(10257):1079-1089. | 2020 | 79.321 |
Corresponding author | Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study | Lancet. 2007 Aug 18;370(9587):567-74. | 2007 | 79.321 |
Corresponding author | Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial | Lancet. 2004 Mar 6;363(9411):751-6. | 2004 | 79.321 |